Multiple sclerosis: open trials in United Kingdom

24 open trials have a site in United Kingdom. Registry data; only the trial team decides who can take part.

NCT06433752
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Research · TG Therapeutics, Inc.
TG Therapeutics Investigational Trial Site, London
Registry updated 2026-10-30
NCT07899502
REAL-MS: Observational Database Study of AHSCT and MS Therapies
Research · Imperial College London
King's College Hospital NHS Foundation Trust, London · University College London Hospitals NHS Foundation Trust, London · Imperial College Healthcare NHS Trust, London
Registry updated 2026-10-27
NCT06846281
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Trial Treatment · Phase 3 · Novartis Pharmaceuticals
Novartis Investigative Site, Leeds · Novartis Investigative Site, London · Novartis Investigative Site, Sheffield · Novartis Investigative Site, Swansea
Registry updated 2026-10-26
NCT07689682
OPM- MEG in Non-immune And iMmune-medIated Neurological Disease
Trial Treatment · Aston University
Birmingham Children's Hospital, Birmingham · Aston University, Birmingham
Registry updated 2026-10-22
NCT07139743
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
Trial Treatment · Phase 1 · Autolus Limited
Addenbrooke's Hospital, Cambridge · Western General Hospital Edinburgh - PPDSE Edinburgh, Edinburgh · The National Hospital for Neurology & Neurosurgery, London · Royal Hallamshire Hospital, Sheffield
Registry updated 2026-10-16
NCT07225504
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Trial Treatment · Phase 3 · Novartis Pharmaceuticals
Novartis Investigative Site, Brighton · Novartis Investigative Site, Bristol · Novartis Investigative Site, Coventry · Novartis Investigative Site, Glasgow · Novartis Investigative Site, Leeds · Novartis Investigative Site, London · Novartis Investigative Site, Nottingham · Novartis Investigative Site, Romford · Novartis Investigative Site, Stoke-on-Trent
Registry updated 2026-10-13
NCT06195800
Identifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation
Research · Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield
Registry updated 2026-10-07
NCT07282574
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Trial Treatment · Phase 2 · Hoffmann-La Roche
University Hospital of Wales, Cardiff · Queen Elizabeth University Hospital, Glasgow · Charing Cross Hospital, London · Royal London Hospital, London · Salford Care Organisation, Salford · Morriston Hospital, Swansea · Royal Cornwall Hospital, Truro
Registry updated 2026-10-07
NCT06450418
Digital App for Speech & Health Monitoring
Research · University of Edinburgh
NHS Lothian, Edinburgh
Registry updated 2026-09-10
NCT03783416
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
Trial Treatment · Phase 1 · Queen Mary University of London
Royal London Hospital, Barts Health NHS Foundation Trust, London
Registry updated 2026-09-08
NCT07224373
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Trial Treatment · Phase 1 · AstraZeneca
Research Site, Cambridge · Research Site, London
Registry updated 2026-08-25
NCT07111637
Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple Sclerosis
Trial Treatment · Queen Mary University of London
Barts Health NHS Trust, London
Registry updated 2026-08-12
NCT05658497
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Research · Biogen
Salford Care Organization, Salford
Registry updated 2026-08-11
NCT07704294
Early Prediction of Outcomes Following Optic Neuritis: Development and Acceptability of a Prognostic Tool
Research · King's College London
King's College Hospital NHS Foundation Trust, London · Guy's and St Thomas' NHS Foundation Trust, London · Moorfields Eye Hospital NHS Foundation Trust, London
Registry updated 2026-07-15
NCT06735248
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
Trial Treatment · Phase 2 · ModernaTX, Inc.
North Bristol NHS Trust - Southmead Hospital, Bristol · Cardiff and Vale University Health Board - University Hospital Wales, Cardiff · Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh · NHS Greater Glasgow & Clyde - Institute of Neurological Sciences, Glasgow · East Kent Hospitals University NHS Foundation Trust, London · Cambridge Clinical Research Centre, London · The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne · Sheffield Teaching Hospital NHS foundation Trust, Herries Road, Sheffield
Registry updated 2026-06-15
NCT06001138
Multiple Sclerosis: FutureMS-2 - an Observational Cohort and Scottish Precision Medicine Study
Research · University of Edinburgh
Aberdeen Clinical Research Facility Royal Cornhill Hospital, Aberdeen · Dundee Clinical Research Centre Ninewells Hospital, Dundee · Anne Rowling Regenerative Neurology Clinic, Edinburgh · Glasgow Clinical Research Facility Queen Elizabeth University Hospital, Glasgow · Centre for Health Sciences Raigmore Hospital, Inverness
Registry updated 2026-05-13
NCT07582653
OCTive: A New Horizon in MS Digital Solution
Research · University of Exeter
University of Exeter Engineering Research Centre, Exeter
Registry updated 2026-05-13
NCT05123443
Longitudinal Assessment of Iron Rims in MS Lesions
Research · Nottingham University Hospitals NHS Trust
Nottingham University NHS Trust, Nottingham
Registry updated 2026-03-12
NCT07452562
Hesperidin RCT in MS
Trial Treatment · Swansea University
FHMLS, Nutrition Lab, Swansea
Registry updated 2026-03-05
NCT05418010
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Trial Treatment · Phase 2 · Queen Mary University of London
St. George's Hospital, London · Royal London Hospital, London
Registry updated 2026-01-07
NCT07303582
Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities
Trial Treatment · Phase 4 · Oxford University Hospitals NHS Trust
Oxford Centre for Enablement (OUH NHS-FT), Oxford
Registry updated 2025-12-26
NCT06966115
Optimising Access to Vocational Rehabilitation for People With Multiple Sclerosis
Trial Treatment · University of Nottingham
University of Nottingham, Nottingham
Registry updated 2025-05-11
NCT06900244
Metabolic Imaging of Neurological Disease
Research · University of Oxford
University of Oxford, Oxford
Registry updated 2025-03-28
NCT06728956
Assessing NHS ImplemeNTation of an onlinE Resilience Training Acceptance and Commitment Therapy (ACT) Programme to Prevent Job Loss in Multiple Sclerosis
Trial Treatment · The Leeds Teaching Hospitals NHS Trust
Leeds Teaching Hospitals NHS Trust, Leeds
Registry updated 2024-12-11

All Multiple sclerosis trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error